Építés alatt – nem éles oldal
Belépés
VisszavonvaFázis nélkül

Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors

A legfontosabb adatok

Ki végzi
University of Cincinnati
Hol
Cincinnati (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Kezdés
2022. júl. 11.
Befejezés
2024. jan. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • RFA controlled using echo decorrelation imaging
  • RFA controlled using standard manufacturer-specified algorithms
A regiszteradat frissítve
2024. augusztus 29.
Miért állt le
Lack of resources to execute study.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years
  • Scheduled for resection of at least one confirmed primary or metastatic liver tumor with estimated diameter <5 cm at the University of Cincinnati Medical Center (UCMC)
  • Patients may have other disease (typically cirrhosis, hepatitis B or hepatitis C) for primary liver cancer patients and extrahepatic cancer (typically colorectal) for metastatic liver cancer patients
  • Ability to understand and the willingness to sign the written research informed consent document for this study

Ki nem vehet részt

  • The tumor for which the resection is scheduled is greater than or equal to 5 cm in diameter
  • The tumor for which the resection is scheduled has received: prior ablation; chemoembolization; or, other treatment which in the opinion of the PI would disqualify a patient from participation
  • Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI
  • Radiofrequency ablation (RFA) is contra-indicated for safety reasons in the opinion of the PI and/or clinical treatment team according to current standards of care (e.g., tumor adjacent to the heart, bowel, gall bladder, or bile ducts; impaired liver function; implanted cardiac devices)
  • Proceduralist assessment that research-specific radiofrequency ablation or intraoperative ultrasound imaging would cause substantial patient risk
  • Pregnant women, prisoners, institutionalized individuals, or other individuals from vulnerable populations

Helyszínek itt: Egyesült Államok

  • University of Cincinnati Medical CenterCincinnati, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will comprise the first pilot clinical trial of 3D, ultrasound-based thermal ablation control using echo decorrelation imaging, directly testing the capability of this approach to ensure reliable tumor treatment. The purpose of this study is to determine the ability of ultrasound echo decorrelation to successfully predict complete ablation of human hepatocellular carcinoma, concomitant diseased liver, and metastatic liver cancer and to determine the potential of echo decorrelation imaging to provide effective real-time control of radiofrequency ablation (RFA) in liver tumors.

A vizsgálat 2 csoportja

  • arm 1: generator-controlled RFAA vizsgált kezelés

    In up to 6 patients (arm 1: generator-controlled RFA), RFA will be performed directly following manufacturer-specified algorithms, with recording of 3D ultrasound echo decorrelation images during ablation.

    Kezelés: RFA controlled using standard manufacturer-specified algorithms

  • arm 2: imaging-controlled RFAA vizsgált kezelés

    In up to 6 additional patients (arm 2: imaging-controlled RFA), real-time, 3D echo decorrelation imaging during ablation will provide an additional treatment end point.

    Kezelés: RFA controlled using echo decorrelation imaging

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. augusztus 29.